Author of

• 20171

  +

  P2.07 - Immunology and Immunotherapy (ID 708)

  • Event: WCLC 2017
  • Type: Poster Session with Presenters Present
  • Track: Immunology and Immunotherapy
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/17/2017, 09:30 - 16:00, Exhibit Hall (Hall B + C)

  • 23412

    +

    P2.07-037 - Developing a Predictive Clinical Outcome Model for Advanced Non-Small Cell Lung Cancer Patients<br /> Receiving Nivolumab (ID 9453)

    09:30 - 09:30  |  Author(s): R. Elias
    • Abstract

    Background:
    Despite significant improvement of clinical outcomes of the patients with advanced non-small cell lung cancer (NSCLC) receiving immune checkpoint inhibitors, our knowledge of optimal predictive and prognostic biomarkers are still evolving.
    
    Method:
    We retrospectively evaluated 159 advanced NSCLC patients who received nivolumab after platinum-based chemotherapy. We correlated several variables with progression free survival (PFS) to develop the iSEND model (Sex, ECOG [Performance status], NLR [Neutrophil-to-Lymphocyte Ratio] & DNLR [Delta NLR = NLR after treatment - pretreatment NLR]). We categorized the patients into good, intermediate, and poor iSEND groups and evaluated clinical outcomes of each group. Performance of iSEND model was evaluated at 3, 6, 9, and 12 months by receiver operating characteristic (ROC) curves. We performed bootstrap internal validation to evaluate the predictive performance of the iSEND model by using the split-sample validation technique. We used logistic regression to correlate different iSEND groups and clinical benefit.
    
    Result:
    The median follow-up was 11.5 months (95% C.I.: 9.4-13.1). There were 50 deaths and 43 other progressions without death. The 3-, 6-, 9-, and 12-months PFS rates were 78.4%, 63.7%, 55.3%, and 52.2% in the good group, 79.4%, 44.3%, 25.9% and 19.2% in the intermediate group, and 65%, 25.9%, 22.8%, and 17.8% in the poor group, respectively. (Figure 1) Time-dependent area under curves (AUC) of the iSEND model for PFS at 3-, 6-, 9-, and 12-months were 0.718, 0.74, 0.746, and 0.774. The poor iSEND group had significant correlation with progressive disease compared to the good group at 12+/-2 weeks. Figure 1. Kaplan-Meier curves for Progression Free Survival of different iSEND model groups Figure 1
    
    
    
    Conclusion:
    The iSEND model is an algorithmic model that can categorize clinical outcomes of advanced NSCLC patients receiving nivolumab into good, intermediate, or poor groups and may be useful as a predictive model.